688 related articles for article (PubMed ID: 27408701)
1. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
Phillips WD; Vincent A
F1000Res; 2016; 5():. PubMed ID: 27408701
[TBL] [Abstract][Full Text] [Related]
2. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
3. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.
Cao M; Koneczny I; Vincent A
Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689
[TBL] [Abstract][Full Text] [Related]
5. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
6. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
7. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
[TBL] [Abstract][Full Text] [Related]
9. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
Higuchi O; Hamuro J; Motomura M; Yamanashi Y
Ann Neurol; 2011 Feb; 69(2):418-22. PubMed ID: 21387385
[TBL] [Abstract][Full Text] [Related]
12. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
13. Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
Bokoliya SC; Kumar VP; Nashi S; Polavarapu K; Nalini A; Patil SA
Clin Chim Acta; 2018 Nov; 486():34-35. PubMed ID: 30006288
[TBL] [Abstract][Full Text] [Related]
14. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
Shen C; Lu Y; Zhang B; Figueiredo D; Bean J; Jung J; Wu H; Barik A; Yin DM; Xiong WC; Mei L
J Clin Invest; 2013 Dec; 123(12):5190-202. PubMed ID: 24200689
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
Mori S; Shigemoto K
Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
[TBL] [Abstract][Full Text] [Related]
17. [Autoantibodies in myasthenia gravis].
Motomura M; Narita Masuda T
Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.
Takamori M
Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365
[TBL] [Abstract][Full Text] [Related]
19. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
20. Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.
Yan M; Liu Z; Fei E; Chen W; Lai X; Luo B; Chen P; Jing H; Pan JX; Rivner MH; Xiong WC; Mei L
Neuroscience; 2018 Mar; 373():113-121. PubMed ID: 29339325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]